Jason Romine, NP
Family · Springfield, MONPI 1285151092
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 95.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $716 and has fallen 78.5% since, to $154 in 2025.
Across 138 payments — averaging $10.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Redhill Biopharma Inc.$21
- Johnson & Johnson$19
- Arbor Pharmaceuticals, Inc.$12
- Biodelivery Sciences International, Inc.$11
What the payments were for
- Food & beverage$1,490100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 134 | $1,426 |
| Redhill Biopharma Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$154
How this compares
$1,490 in reported general payments places this provider in the 75th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 34 | $33,027 |
| Sucralfate | 39 | $4,845 |
| Lubiprostone | 14 | $3,989 |
| Omeprazole | 86 | $2,123 |
| Pantoprazole Sodium | 71 | $1,758 |
| Dicyclomine Hcl | 19 | $969 |
| Lactulose | 12 | $711 |
| Famotidine | 45 | $559 |
| Neomycin Sulfate | 14 | $392 |
Paid to pharmacies, not to this prescriber.
Other family in Springfield
- Laura HedigerSpringfield$71K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.